PolyPeptide Group’s Post

View organization page for PolyPeptide Group, graphic

20,359 followers

Upgrade of 2024 guidance and mid-term outlook to double 2023 revenues by 2028. We are happy to share our financial results for H1 2024 and our new mid-term outlook, released earlier today. With solid progress and improved profitability and cash flow, we increased our guidance for 2024. As we strive to be the most innovative peptides CDMO, we now target to double 2023 revenue by 2028, with the EBITDA margin approaching 25%. 👉 https://lnkd.in/dWcKi6zY   #halfyearresults #CDMO #peptides  

Best of luck!

Like
Reply
Rajesh Thakur (PMP)® LSSBB

Project Manager RGP | Ex- Hikal Ltd | Ex-Sun pharma |Ex-Dishman Carbogen Amcis | Key Account Manager for MNC's

2mo

Impressive growth!

Like
Reply
Isak Hallberg

M.Sc.(Eng) in Biotechnology, spec. Molecular Biology

2mo

Imponerande!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics